71 results about "Lipid deposition" patented technology

The present invention relates to a stress stable lathering skin cleansing liquid composition comprising by weight parts of the liquid composition: (a) from about 0.5 parts to 10 parts of a stabilizer; for example trihydroxystearin; (b) from about 1 part to about 80 parts of lipid skin moisturizing agent; (c) from about 1 part to about 30 parts of surfactant having a combined CMC equilibrium surface tension value of from 15 to 50; (d) water; wherein said stress stable lathering skin cleansing liquid composition has a Lipid Deposition Value (LDV) of from about 5 to about 100 and wherein said composition is stable for at least two weeks at 100 F.

This invention relates generally to a method for treatment of lens surfaces by first coating the mold material with a reactive macromonomer and subsequently casting and curing the lens forming material along with the coating material present on the surface of the mold. The macromonomer reacts with the lens monomer mix and is covalently bound to the lens matrix. The modified lenses may ultimately show enhanced wettability, inhibition of bacterial adhesion and lower levels of protein and lipid deposition leading to increased comfort and longer wearing times.

The invention provides a coffee mate product prepared from pine nuts, belongs to the field of a beverage processing biotechnology, and relates to a coffee mate product adopting pine nut oil microcapsules to be matched with coffee drinks. The coffee mate product is prepared from 60%-80% by weight of pine nut oil microcapsule powder and 20%-40% by weight of sucrose. The pine nut oil microcapsule powder of the coffee mate contains rich unsaturated fatty acid and especially has the highest linoleic acid content; the unsaturated fatty acid can promote cholesterol metabolism, reduce blood lipid and increase the content of high-density lipoprotein in serum, prevent lipid deposition on a liver and an arterial wall, reduce platelet cohesion and reduce thrombosis, and the coffee mate product prepared from the pine nuts is ideal food for protection of blood vessels of the crowd with hyperlipidemia.

Compositions and methods for cleaning contact lenses employing nonionic surfactants having HLBs greater than about 18 with the nonionic surfactant having a greater HLB present in an amount about twice that of the nonionic surfactant having a lower HLB, and provided in an amount effective to reduce the amount of lipids on the contact lenses, thus rendering the contact lenses easier to clean. Additionally, by soaking contact lenses in the composition prior to inserting the lens on the eye, the compositions provide a prophylactic effect in preventing lipid deposition while the contact lens is worn.

This invention is directed to an aqueous composition and methods for cleaning lipid deposits and / or prevention of lipid deposition on contact lenses. In particular, a combination of non-ionic surfactants, straight chain poly(ethylene oxide-propylene oxide-ethylene oxide) (PEO—PPO—PEO) block copolymers having HLB value greater than or equal to 18, with an additional straight chain poly(ethylene oxide-propylene oxide-ethylene oxide) (PEO—PPO—PEO) block copolymer having an HLB value less than or equal to 11, has been found to improve the lipid cleaning properties of an aqueous composition for contact lenses and prevent the overgrowth of harmful bacteria, yeast and molds without adversely affecting the comfort or safety in terms of the level of toxicity to eye tissue.

The invention discloses an anther tapetum specific expression promoter POsABCG15. The promoter has a nucleotide sequence shown as SEQ ID NO. 31. The promoter can regulate and control a target gene, so that the target gene is expressed to anther tapetum specifically; and the POsABCG15 in rice regulates and the controls the expression of a lipid deposition gene OsABCG15 on anther epidermis and pollen wall of the rice and influences the accumulation of lipids on surfaces of anther and pollen, so that the anther tapetum specific expression promoter POsABCG15 can be used for generating a new rice male sterile line or regulating and controlling the expression of other genes in the tapetum, and has an important effect in agricultural production.

The invention discloses a Chinese medicinal composition for clearing heat and losing weight, and the Chinese medicinal composition comprises the following components in parts by weight: 8-19 parts of ganoderma lucidum, 7-20 parts of cassia seeds, 15-30 parts of watermelon peel, 10-30 parts of waxgourd peel, 9-20 parts of hawthorn, 5-18 parts of lotus leaf, 6-17 parts of corn stigma, 10-25 parts of licorice, 8-24 parts of siraitia grosvenorii, 7-22 parts of honeysuckle flower and 6-23 parts of chrysanthemum morifolium. The Chinese medicinal composition adopting naturally green materials can be used for effectively clearing heat in a human body, reducing lipid deposition in the body and discharging toxin in the human body.

The present invention relates to moisturizing personal cleansing compositions comprising a lathering surfactant and a lipophilic skin moisturizing agent wherein the moisturizing personal cleansing composition has a Lipid Deposition Value of greater than or equal to about 25 micrograms / square centimeter. The invention further relates to moisturizing personal cleansing composition comprising from about 85% to about 95% of a neat cleansing lotion comprising from about 0.5% to about 30% by weight of the neat cleansing lotion, of a lathering surfactant; from about 0.5% to about 33% by weight of the neat cleansing lotion, of a lipophilic skin moisturizing agent; from about 0.1% to about 2% by weight of the neat cleansing lotion, of a stabilizer; and from about 35% to about 90% by weight of the neat cleansing lotion, of water; and from about 3% to about 15% of a hydrocarbon propellant wherein the moisturizing personal cleansing composition has a Deposition Value of greater than or equal to about 25 micrograms / square centimeter.

The present invention relates to novel pharmaceutical compositions comprising Epimedium wushanense Ying extracts, their methods of preparation, and their use in inhibiting thrombosis and lipid deposition. Also provided by the present invention is a method of preventing or treating steroid-associated osteonecrosis with the use of the pharmaceutical composition of the present invention. The preparation method of the present invention is stable and provides reproducible results, both in small scale extraction and large scale extraction.

The invention provides a fleece-flower root life-prolonging tablet for treating baldness according to the theory that the baldness is treated in need of treating liver and kidney firstly. The formula of the fleece-flower root life-prolonging tablet is as follows according to the weight ratio: 300-400 parts of polygonum multiflorum, 18-22 parts of rehmannia, 14-20 parts of semen sesami nigrum, 30-50 parts of the root of bidentate achyranthes, 150-200 parts of mulberry, 30-50 parts of fructus ligustri lucidi, 200-250 parts of eclipta, 30-50 parts of folium mori, 70-90 parts of semen cuscutae, 230-280 parts of fructus rosae laevigatae, 30-50 parts of fructus psoraleae, 60-100 parts of phlomis bracteosa royle and 15-25 parts of honeysuckle. The modern pharmacology research shows that the fleece-flower root life-prolonging tablet has the functions of resisting free radicals, preventing lipid peroxidation, reducing activity of monoamine oxidase, enhancing the function of adrenal gland and the like; in addition, the fleece-flower root life-prolonging tablet can lessen the formation of experimental atheromatous plaques and lipid deposition, so as to exert the functions of reducing blood fat and resisting atherosclerosis.

The invention provides a milk powder product prepared from pine nuts, belongs to the field of a beverage processing biotechnology, and relates to a milk powder product adopting pine nut oil microcapsules. The milk powder product is prepared from 30%-40% by weight of pine nut oil microcapsule powder and 60%-70% by weight of milk powder. The pine nut oil microcapsule powder of the milk powder contains rich unsaturated fatty acid and especially has the highest linoleic acid content; the unsaturated fatty acid can promote cholesterol metabolism, reduce blood lipid and increase the content of high-density lipoprotein in serum, prevent lipid deposition on a liver and an arterial wall, prevent platelet cohesion and reduce thrombosis, and the milk powder product prepared from the pine nuts is ideal food for protection of blood vessels of the crowd with hyperlipidemia.

The invention relates to applications of a transcription factor CREB in JHDM2A gene expression regulation and pig lipid deposition reduction. By overexpression of CREB in pigs, or by improvement of the CREB phosphorylation level in pigs, or by promotion of combination of pig CBP protein and the phosphorylated CREB, JHDM2A gene expression in pigs is up-regulated, thus regulating lipid metabolism pathways from the epigenetics and reducing pig lipid deposition. Novel applications of the transcription factor CREB in the epigenetics are provided for the first time and the transcription factor CREB can be used for reducing pig lipid deposition, namely, expression of the histone demethylase JHDM2a is directly activated so that the histone demethylase JHDM2a can regulate the lipid metabolism pathways from the epigenetics, thus minifying lipid cells and increasing the meat factor. A novel candidate gene is provided for genetic breeding, meat quality improvement, and the like in the animal husbandry.

The invention belongs to the field of lipid-lowering products, particularly relates to a konjac and red yeast rice compound lipid-lowering capsule and also relates to a preparation method of the capsule. The compound lipid-lowering capsule is characterized by being prepared from the following components in parts by weight: 300-400 parts of konjac refined flour and 100-200 parts of red yeast rice powder. The compound lipid-lowering capsule has the beneficial effects that the konjac refined flour is combined with the red yeast rice powder for synergistic action, so that the compound lipid-lowering capsule has the functions of regulating blood fat, reducing serum cholesterol, triglyceride, low-density lipoprotein cholesterin and increased high-density lipoprotein cholesterol, inhibiting formation of atherosclerotic plaques, protecting vascular endothelial cells and inhibiting lipid deposition in the liver.

The invention discloses application of balanophora involucrate extract to preparation of a medicine for treating hepatitis. A total extract obtained by decocting the balanophora involucrate, a water extraction and alcohol precipitation part, and an ethyl acetate part are in in vitro AML12 cells, secretion of inflammatory cytokines such as PA-stimulated TNF-alpha and IL-1beta can be obviously inhibited, and expressions of mRNAs of inflammatory cytokines such as TNF-alpha and IL-1beta can be inhibited; and the expressions of mRNAs of inflammatory cytokines such as TNF-alpha and IL-1beta in HFD-induced liver tissue of mice can both be obviously inhibited in vivo. Meanwhile, lipid deposition in liver tissue of mice with alcoholic hepatitis can be effectively improved by the water extraction and alcohol precipitation part of the balanophora involucrate, inflammatory cell infiltration is reduced, activities of mice serum ALT and AST and expression level of inflammatory cytokines of TNF-alpha, IL-1beta, IL-6, and NLRP3, and the protective effects of lipid deposition inhibition and inflammatory reaction resistance to alcoholic hepatitis are achieved. According to the extract, during animalexperiments, no mouse is found dead, no obvious abnormal renal and liver function is observed in the mice, and it is indicated that the medicine has good safety.

The invention relates to methods of screening agents for the ability to regulate lipid metabolism and using said agents to treat diseases or disorders related to lipid metabolism (e.g., obesity, diabetes [non-insulin and insulin dependent], hypertension, coronary artery disease, hyperlipidemia (e.g., LDL, TAGs), hypolipidemia (e.g., HDL), lipid metabolism disorders, lipid deposition disorders, lipodystrophies). In specific embodiments, the invention relates to using a PAT family protein to screen agents for the ability to regulate lipid metabolism and using the same to treat diseases or disorders related to lipid metabolism. In further embodiments, the invention relates to high throughput screening (HTS) methods that can be used in the drug discovery process for screening agents for the ability to regulate lipid metabolism.

The invention discloses application of novel loquat leaf sesquiterpene glycoside in relieving liver cell lipid deposition, and also discloses application in preparation of drugs and health-care foodsfor preventing or treating non-alcoholic fatty liver. The name of the sesquiterpene glycoside is nerolidol-3-O-alpha-L-arabinopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1-> 2)-[alpha-L-rhamnopyranosyl-(1-> 6)]-beta-D-glucopyranoside.

The invention discloses a traditional Chinese medicine composition for losing weight. The traditional Chinese medicine composition is prepared from, by weight, 10-30 parts of fructus crataegi, 10-20 parts of radix puerariae, 10-15 parts of pinenut kernels,9-17 parts of pericarpium citri reticulatae, 8-14 parts of radix codonopsis, 8-12 parts of semen cassia, 7-12 parts of fructus forsythia, 6-10 parts of folium sennae, 6-9 parts of rhizoma atractylodis macrocephalae, 5-10 parts of herba dendrobii, 5-9 parts of semen plantaginis and 3-6 parts of herba taraxac. The selected materials are natural and environmentally friendly, the traditional Chinese medicine composition can reduce phlegm, eliminate fat, invigorate the spleen and eliminate dampness and regulate functional activities of qi, can effectively clear heat in the human body, reduce lipid deposition reduction in the human body and discharge toxin in the human body and is free of side effect on the human body, suitable for treating female obesity, simple in formula, low in cost and definite in curative effect, a patient is free of side effects of anorexia, diarrhea and the like, nourishing and weight losing are achieved, and immunity of the organism is improved.

The invention relates to a traditional Chinese medicinal formula, and especially relates to a traditional Chinese medicinal formula for treating hypertension. The formula comprises 15-36g of prepared rehmannia root, 6-20g of Cornus officinalis, 6-20g of Chinese yam, 3-15g of Poria cocos, 3-20g of Rhizoma Alismatis, 3-20g of Cortex Moutan, 2-15g of tangerine pericarp, 2-15g of cassia seed, 2-10g of cinnamon and 5-15g of Achyranthes bidentata. The formula aims at the main reasons of hyperactivity of liver-yang, yang hyperactivity and yin deficiency of hypertension patients, and nourishes liver and kidney yin to reduce lipid deposition on aorta walls, reduce blood fat and improve kidney functions in order to reduce the blood pressure. The above formula also has blood sugar reducing, liver cell protecting and tumor preventing effects, realizes simultaneous treatment of principal and subordinate symptoms, and has no toxic or side effects. When the formula is clinically taken by 236 patients, the effective rate is 100%, and the cure rate is 93.6% or above.

The invention discloses a low-acid-value Yunnan pine seed oil and a preparation method thereof, the invention further provides an application of the pine seed oil in foods and treatment of cardiovascular and cerebrovascular diseases and other diseases. The capsule disclosed by the invention can promote normal metabolism of cholesterol, so that the plasma cholesterol can be reduced, the function of promoting lipid deposition in the endothelial cells of the artery by blood platelets can be obviously inhibited, the blood platelet aggregation can also be reduced, the thrombosis can be inhibited, and the fasting blood glucose of a patient can be remarkably improved.

The invention discloses concentrated feed containing cysteamine hydrochloride feed additive for promoting healthy growth of animals, prepared from 15-20 parts of corn meal, 5-10 parts of wheat bran, 50-70 parts of fresh chicken manure, 6-10 parts of fish meal, 3-5 parts of brown sugar, 10-20 parts of soybean meal, 2-3 parts of a fermenting bacteria liquid, 1-3 parts of sunflower oil, and 4-10 parts of cysteamine hydrochloride feed additive, wherein the cysteamine hydrochloride feed additive comprises 0.01-0.02 part of cysteamine hydrochloride, 25-40 parts of glucose, 30-40 parts of vitamin E, 10-20 parts of soybean flavones, and 10-20 parts of vitamin C. The concentrated feed has the functions in animal mentalism, such as adjusting nutrient metabolism, promoting protein synthesis, reducing lipid deposition, promoting body growth and improving feed availability, can finally promote quick and healthy growth of animals and has good taste.

The invention discloses application of a substance for inhibiting phosphorylation of a 357 tyrosine residue of a YAP protein to prevention of atherosclerosis. The substance for inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein is an Src / c-Abl tyrosine kinase double inhibitor or a c-Abl inhibitor or an Src inhibitor; bosutinib is adopted as the Src / c-Abl tyrosine kinase double inhibitor; and experiments prove that the bosutinib prevents atherosclerosis, treats atherosclerosis, decreases the area of plaques of atherosclerosis, reduces lipid deposition, decreases the collagen content, inhibits forming of the plaques of atherosclerosis, inhibits activation of vascular endothelial cells and inhibits the expression level of adherence factors by inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein. The substance has significant application value.

The invention discloses a novel medicine for preventing and treating heart diseases, the main component of the medicine is non-binding bilirubin, and the medicine is used for preventing the heart diseases, further reducing the incidence of the heart diseases, reducing sudden death or heart failure, improving the life quality of patients with the heart diseases and improving the prognosis. The non-binding bilirubin has stronger effects of resisting oxidation, resisting inflammation, inhibiting cell proliferation, inhibiting platelet activation, promoting cholesterol metabolism and the like, and can achieve the effects of preventing atherosclerosis, protecting vascular endothelial cells and smooth muscle cells, protecting myocardium, preventing lipid deposition, reducing atheromatous plaque formation and reducing myocardial damage. In view of low water solubility of the unbound bilirubin, the oral unbound bilirubin is mixed with the olive oil or the fish oil to be stored in the capsule, so the absorption of the unbound bilirubin can be promoted, and the bilirubin can be protected from being oxidized.

The invention discloses a polypeptide compound for treating and / or preventing non-alcoholic steatohepatitis. The polypeptide compound has the characteristics of high biological activity, no adverse reaction and the like, and can obviously inhibit lipid deposition in liver and improve fatty liver and inflammatory degree. The polypeptide compound can be used for preparing medicines for preventing and / or treating non-alcoholic steatohepatitis.

The invention provides the application of the verbascoside in the preparation of the medicine for preventing and / or treating hyperlipidemia and atherosclerosis, the application prospect of the verbascoside is developed, and a theoretical basis and guidance are provided for the development of a new medicine for resisting atherosclerosis. The verbascoside is proved to be capable of remarkably reducing the foaming degree of oxidized low-density lipoprotein induced macrophages in vitro, reducing the cholesterol level and remarkably relieving formation of arterial plaques in a western diet induced atherosclerosis animal model at the same time; the verbascoside can relieve lipid deposition in the liver by adjusting a glycerophospholipid metabolic pathway in the liver, adjust lipid metabolism disorder and reduce the blood fat level, so that the effect of resisting atherosclerosis is achieved.

The present invention relates to a cytosolic isocitrate dehydrogenase, its gene, and its use in the treatment of obesity, hyperlipidemia, and fatty liver. The expression of the IDPc gene and the concomitant increase in IDPc level bring about an increase in the cellular level of NADPH, which causes the lipid deposition in adipocytes, leading to obesity and fatty liver. A decrease in the cellular level of NADPH, resulting from the suppression of the gene expression of IDPc, has the effect of inhibiting the lipid deposition in adipocytes. Further, by taking advantage of the suppressive or inhibitory effects of isocitrate dehydrogenase inhibitors, pharmaceutically effective materials for the prophylaxis and treatment of obesity, hyperlipidemia and fatty liver can be developed.

The invention belongs to the field of pharmacies and particularly relates to a drug for treating hyperlipidemia. The composition for treating the hyperlipidemia comprises the following components in parts by weight: 15-25 parts of processed polygonum multiflorum, 10-20 parts of glossy privet fruit, 2-4 parts of coptis, 10-20 parts of rhizoma alismatis, 10-14 parts of peach seed, 15-25 parts of kudzuvine root, 10-20 parts of capillary artemisia, 8-12 parts of giant knotweed rhizome, 8-12 parts of dried orange peel, 8-12 parts of raw hawthorn and 10-20 parts of cassia occidentalis. A preparation method of a preparation of the composition comprises the steps of smashing, screening, mixing, soaking, decocting for 40-50 minutes at the temperature of 100 DEG C through taking an extraction pot as a decoction vessel to obtain the preparation. The preparation is capable of improving the states of high viscosity and hypercoagulation of blood, obviously scavenging free radicals, resisting lipid peroxidation, reducing blood fat of experimental animals and inhibiting endarterium plaque formation and lipid deposition and has the effects of reducing blood fat, inhibiting platelet aggregation and resisting thrombus; the preparation made from pure Chinese herbal medicines is pure and mild in property, little in side effect and considerable in effect.

The invention relates to a traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque, belonging to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine capsule is prepared from the following raw materials by weight: 30 to 40 parts of yeast powder, 11 to 21 parts of prepared rhubarb, 5 to 15 parts of pseudo-ginseng, 3 to 10 parts of glutinous rehmannia, 4 to 15 parts of prepared leech, 1 to 10 parts of stir-fried ground beetle, 1 to 9 parts of stir-fried gadfly, 1 to 8 parts of calcined dried lacquer, 1 to 5 parts of licorice root, 2 to 7 parts of root of large-flowered skullcap, 2 to 10 parts of peach seed, 5 to 10 parts of safflower and 5 to 10 parts of stir-fried bitter apricot kernel. The yeast powder, rhubarb, leech, ground beetle and gadfly in the capsule are used for reducing blood fat, removing plaque and resisting hemagglutination; removed plaque will not form thrombus, so blood vessels will not be blocked; lipid deposition in a body is reduced; metabolic disorders of a body are adjusted; oxidation damage is mitigated; and inflammatory response is inhibited. The root of large-flowered skullcap in the raw materials exerts anti-inflammation effect. The pseudo-ginseng, peach seed, dried lacquer, safflower and bitter apricot kernel are capable of activating blood circulation to dissipate blood stasis. Through combined usage of the bulk drugs, the prepared traditional Chinese medicine capsule is capable of reducing blood fat and removing atherosclerotic plaque and has good clinical application effect.

The invention provides an application of rotundine in preparation of a medicine for treating fatty liver, and belongs to the field of medicines. The invention mainly provides application of a compoundshown as a formula I or salt thereof in preparation of the medicine for treating the fatty liver and / or lowering lipid. Researches find that the rotundine can significantly inhibit lipid deposition in the liver of a fatty liver patient, has a lipid lowering effect, a good treatment effect on the fatty liver, and no harm to the health of the fatty liver patient, and provides a novel method for treating the fatty liver; and meanwhile, the method is a novel use of the old medicine, can greatly save the development time and cost, is more detailed in listed pharmacokinetics and safety data, can achieve the second-stage clinical evaluation through the development of the novel use, shortens the research and development period, saves the development cost, and achieves the maximum utilization of resources.